About this document
Frigeiro 2019 by garbeliniluan is a document available to read on EtoBox.
The study investigates the use of anti-PSMA 124I-scFvD2B as an immuno-PET tool for prostate cancer, demonstrating its high specificity and sensitivity in targeting PSMA-positive tumors in a preclinical model. Results show a significant uptake of the radiolabeled antibody in PSMA-positive tumors compared to PSMA-negative ones, with a median target/background ratio of 30-40. These findings suggest that 124I-scFvD2B could enhance diagnostic capabilities for prostate cancer when combined with imaging modalities
- Author
- garbeliniluan
- Language
- EN